Inhibikase Therapeutics (IKT) Free Cash Flow (2020 - 2026)
Inhibikase Therapeutics (IKT) posted quarterly Free Cash Flow of -$12.1 million for Q1 2026, down 192.93% year-over-year from $13.0 million in Q1 2025, and down 60.45% quarter-over-quarter from -$7.5 million in Q4 2025.
Inhibikase Therapeutics (IKT) Free Cash Flow (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Free Cash Flow for 7 consecutive years, with -$12.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 192.93% year-over-year to -$12.1 million; the TTM figure through Mar 2026 stood at -$35.7 million (down 84.26% YoY), while the FY2025 annual figure was -$27.8 million, down 45.18% from the prior year.
- Free Cash Flow retreated to -$12.1 million in Q1 2026 per IKT's latest filing, from -$7.5 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$3.4 million in Q4 2023 and bottomed at -$12.1 million in Q1 2026.
- Historically, Free Cash Flow has averaged -$5.6 million across 5 years, with a median of -$4.9 million in 2024.
- Annual changes were most pronounced in 2024 — Free Cash Flow jumped 35.25% — and 2026, when it slumped 192.93%.
- Inhibikase Therapeutics' Free Cash Flow stood at -$3.6 million in 2022, then grew by 3.2% to -$3.4 million in 2023, then plunged by 55.28% to -$5.3 million in 2024, then slumped by 40.6% to -$7.5 million in 2025, then tumbled by 60.45% to -$12.1 million in 2026.
- Business Quant data shows IKT's Free Cash Flow at -$12.1 million in Q1 2026, -$7.5 million in Q4 2025, and -$10.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - | -12.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12.44 Mn |
| Jun 30, 2026 | -12.44 Mn |
| Mar 31, 2026 | -12.06 Mn |
| Mar 31, 2026 | -12.06 Mn |
| Dec 31, 2025 | -7.52 Mn |
| Dec 31, 2025 | -7.52 Mn |
| Sep 30, 2025 | -10.59 Mn |
| Sep 30, 2025 | -10.59 Mn |
| Jun 30, 2025 | -5.57 Mn |
| Jun 30, 2025 | -5.57 Mn |
| Mar 31, 2025 | -4.12 Mn |
| Mar 31, 2025 | -4.12 Mn |
| Dec 31, 2024 | -5.35 Mn |
| Dec 31, 2024 | -5.35 Mn |
| Sep 30, 2024 | -4.88 Mn |
| Sep 30, 2024 | -4.88 Mn |
| Jun 30, 2024 | -5.05 Mn |
| Jun 30, 2024 | -5.05 Mn |
| Mar 31, 2024 | -3.87 Mn |
| Mar 31, 2024 | -3.87 Mn |